← Back to Search

Monoclonal Antibodies

NJH395 for HER2 Positive Malignancies

Phase 1
Waitlist Available
Research Sponsored by Novartis Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2.5 years
Awards & highlights

Summary

A first-in-human study using NJH395 in non-breast HER2-positive advanced malignancies

Eligible Conditions
  • HER2 Positive Malignancies

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2.5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2.5 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Incidence and severity of dose limiting toxicities (DLTs)
Secondary study objectives
Characterization of tumor-infiltrating lymphocytes by IHC
Clinical Benefit Rate (CBR)
Duration of Response (DOR)
+2 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: NJH395Experimental Treatment1 Intervention
Includes non-breast HER2-positive advanced malignancies
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
NJH395
2018
Completed Phase 1
~20

Find a Location

Who is running the clinical trial?

Novartis PharmaceuticalsLead Sponsor
2,893 Previous Clinical Trials
4,200,933 Total Patients Enrolled
~3 spots leftby Oct 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top